Non-Interventional Study (NIS) Protocol
 
Document Number: c42255024-02
BI Study Number: 1199-[ADDRESS_77156](s):
Title:Economic burden associated with nintedanib non-adherence among 
Medicare beneficiaries with IPF
Brief lay title: Burden of nintedanib non-adherence among IPF patients
Protocol 
version identifier:3.[ADDRESS_77157] version 
of protocol:Not applicable
PASS:
EU PAS 
register 
number:NA
Active substance: <List of pharmacotherapeutic group(s) (ACT codes) and 
active substance(s) subject to the study, if applicable>
Medicinal product: Nintedanib (Ofev)
Product reference: <Reference number(s) of centrally authorised products 
and/or, if possible, of nationally authorised products subject 
to the study, if applicable>
Procedure number: Not applicable
Marketing 
authorisation holder(s):<Marketing authorisation holder(s) which initiate(s), 
manage(s) or finance(s) the study>
Joint PASS: No

001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 2 of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Research question and objectives:1) To quantify the association between nintedanib adherence trajectory 
group (as measured from a group-based trajectory model or GBTM) and health care resource use, with a focus on inpatient 
hospi[INVESTIGATOR_059], among patients with IPF.
2)To quantify the association between a patient‚Äôs nintedanib 
adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Country(-ies) of study: [LOCATION_002]
Author:
Marketing 
authorisation holder(s):<Name, address and contact [CONTACT_70792](s)>
Date: 05/09/2023
Page 1 of 35
Proprietary confidential information
¬© [ADDRESS_77158]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 3of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77159]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 4of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
10.1 STUDY APPROVAL, PATIENT INFORMATION, AND INFORMED 
CONSENT .......................................................................................................................2 8
10.2 STATEMENT OF CONFIDENTIALITY ....................................................28
11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE
REACTI ONS ...................................................................................................................... .....[ADDRESS_77160]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 5of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77161]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 6of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77162]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 7of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77163]
Name [CONTACT_23359]:
Boehringer Ingelheim
Name [CONTACT_70819]:
Nintedanib (Ofev)
Name [CONTACT_23361]:
Nintedanib (Ofev)
Protocol date:
9 May 2023Study 
number:
1199-
0520Version/Revision:
5.0Version/Revision date:
19 April 2023
Title of study: Economic burden associated with nintedanib non-adherence among 
Medicare beneficiaries with IPF
Rationale 
and background:Recent systematic reviews found links between medication non-
adherence and higher healthcare spending ( Cutler et al., 2018 ) and 
elevated risks of inpatient hospi[INVESTIGATOR_47144] ( Walsh et al ., 
2019 ).  To our knowledge, however, there have been no studies 
examining the association between non-adherence and economic burden specific to nintedanib, antifibrotics, or idiopathic pulmonary fibrosis (IPF).
A prior study by [CONTACT_70793]-based trajectory modelling (GBTM) and identified characteristics of patients associated with membership in each trajectory group.  A handful of existing studies examine associations between medication non-adherence as measured from GBTM and coincident or subsequent health care resource use, although none were specific to the setting of interest here.  This study seeks to build on our prior study and fill that gap in knowledge.  We expect the findings from this study to be highly relevant to clinicians and payers to help optimize care in a cost-effective manner.
Research question and objectives: 1) Assess the association between nintedanib adherence trajectory group 
(as measured from a GBTM) and health care resource use, with a focus on inpatient hospi[INVESTIGATOR_059], among patients with IPF.
2) Assess the association between a patient‚Äôs nintedanib 
adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Study design: This is a non-interventional, retrospective cohort study.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 8of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Name [CONTACT_23359]:
Boehringer Ingelheim
Name [CONTACT_70819]:
Nintedanib (Ofev)
Name [CONTACT_23361]:
Nintedanib (Ofev)
Protocol date:
9 May 2023Study 
number:
1199-
0520Version/Revision:
5.0Version/Revision date:
19 April 2023
Population: The study sample will consist of community-dwelling Medicare 
beneficiaries with IPF who initiate treatment with nintedanib.
Variables: The main exposure will be a five-category measure of adherence 
trajectory to nintedanib in the year following initiation.
Outcomes will reflect inpatient hospi[INVESTIGATOR_059] (any and number of 
days) and health care spending for both all-cause and IPF-related care.
A range of covariates will be measured during the baseline period and 
at the index date, including baseline patient demographic characteristics (e.g., age, sex, race/ethnicity), residential location, clinical characteristics (e.g., comorbidity index, IPF-related health care costs and use), and all-cause health care costs and use.
Data sources: This study will use administrative enrollment and claims data from the 
U.S. federal Medicare program for beneficiaries aged 65 years and 
older who were continuously enrolled in Original Medicare insurance 
coverage, including Parts A, B and D.  The study will use Medicare 
data covering the period from October 1, 2013, through December 31, 
2020.
Study size: Based on our prior study, the sample for analysis of the primary 
outcomes will consist of 1,798 Medicare beneficiaries with IPF who initiated nintedanib between October 1, 2014, and December 31, 2018. The sample available for the secondary outcomes will be smaller by [CONTACT_70794]-up.
Data analysis: Mean health care cost and use outcomes will be compared between 
pairs of nintedanib adherence trajectory membership categories using a 
regression modeling framework.  Unadjusted means will be compared first using an ‚Äúempty‚Äù linear regression model specification (with no covariates or weights).  Adjusted means will then be compared using a ‚Äúdoubly robust‚Äù generalized linear model (GLM) specification.  
Potential confounding by [CONTACT_70795].  The first way will be to calculate observation-level inverse propensity weights that balance covariates 
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 9of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Name [CONTACT_23359]:
Boehringer Ingelheim
Name [CONTACT_70819]:
Nintedanib (Ofev)
Name [CONTACT_23361]:
Nintedanib (Ofev)
Protocol date:
9 May 2023Study 
number:
1199-
0520Version/Revision:
5.0Version/Revision date:
[ADDRESS_77164] will be through 
regression adjustment; that is, observed covariates will be added to the GLM specification.
Milestones: Final report of this study is expected to be available for review by [CONTACT_9179]
15th, 2023.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 10of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77165]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 11of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6. MILESTONES
Milestone Planned Date
Final report 05/15/2023
Poster draft TBD
Poster BI approval (all steps in 
DataVision)TBD
Manuscript draft TBD
Manuscript BU approval (all steps in 
DataVision)TBD
Publication TBD
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 12of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7. RATIONALE AND BACKGROUND
It is taken as self-evident in the medical community that medication non-adherence leads to 
negative outcomes; as C. Everett Koop said, ‚ÄúDrugs don‚Äôt work in patients who don‚Äôt take them‚Äù ( Osterberg and Blaschke, 2005 ).  Recent systematic reviews of the published literature 
found links between medication non-adherence and higher spending ( Cutler et al., 2018 ) and 
elevated risks of inpatient hospi[INVESTIGATOR_47144] ( Walsh et al., 2019 ).  To our 
knowledge, however, there have been limited studies examining the association between non-adherence and economic burden specific to nintedanib, antifibrotics, or idiopathic pulmonary fibrosis (IPF).
Measuring medication adherence is difficult.  There are several approaches to measuring 
adherence, each with its own strengths and limitations ( Forbes et al., 2018 ).  A common 
method in real-world settings, such as prescription drug claims databases, is the proportion of days covered (PDC), which is defined for a specific medication as the number of days 
supplied divided by [CONTACT_70796] ( Anghel et al., 2019 ).  
Although PDC is useful in that it offers in a single number a metric of medication adherence over a predefined period, its simplicity masks any heterogeneity in adherence between patients and specifically does not capture changes in individual patient adherence over time.  
An alternative approach is to use group-based trajectory modelling (GBTM) to detect 
trajectories of medication adherence over time and identify clusters of individuals who follow similar longitudinal adherence patterns ( Nagin and Odgers, 2010 ).  GBTM has been used to 
understand adherence to medications in several therapeutic areas ( Alhazami et al., 2020 ).  
Longitudinal evaluation of medication adherence using GBTM can yield more informative classifications compared to traditional methods such as PDC ( Franklin et al., 2013 ).
A prior study by [CONTACT_70797].  Individuals with idiopathic pulmonary fibrosis (IPF) who initiated nintedanib during 10/1/2014‚Äì12/31/2018 were identified in 100% Medicare claims and enrollment data.  The sample consisted of community-dwelling older adults ( ‚â•66 years) with continuous coverage 
in Medicare Parts A, B and D for one year before (baseline) and after (follow-up) starting nintedanib.  PDC was calculated for each of 12 consecutive 30-day months based on nintedanib claim fill dates and days‚Äô supply.  PDC was dichotomized, with PDC ‚â•0.[ADDRESS_77166]-fitting GBTM had five adherence trajectory groups: highly adherent 
(43.1%), medium adherent (11.9%), gradual decliners (10.4%), intermediate decliners (13.2%), and rapid decliners (21.5%) ( Figure 1 ).  The principal factors associated with higher 
odds of being in at least one of the lower-adherence groups were older age, female sex, race and ethnicity other than non-Hispanic white, and taking an additional medication during baseline.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 13of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
A handful of existing studies examine associations between medication non-adherence as 
measured from GBTMs and coincident or subsequent health care resource use.  Dillon et al. (2019 ) found lower GBTM-based adherence to antihypertensive medications was associated 
with a higher rate of visits to general practitioners but not hospi[INVESTIGATOR_70774].   Franklin et al. ( 2015 ) found lower GBTM-based adherence to statin medications was 
associated with higher risk of clinical events as measured by a composite of hospi[INVESTIGATOR_70775], revascularization, a cerebrovascular event and heart failure in a large commercial insurance claims database in the [LOCATION_002].  A pair of studies by [CONTACT_70798]-Ciganic and colleagues used Medicaid claims data from Pennsylvania.  They found lower GBTM-based adherence to buprenorphine led to higher risk of hospi[INVESTIGATOR_70776] (ED) visits ( Lo-Ciganic, Gellad, et al., 2016 ), and lower GBTM-based adherence 
to oral hypoglycemic medications led to higher risk of diabetes-related hospi[INVESTIGATOR_602]/ED visits.
This study seeks to fill the gap in knowledge about the potential association between 
adherence to nintedanib and patients‚Äô health care resource use and spending.  We expect the findings from this study to be highly relevant to clinicians and payers to develop actionable strategies to improve adherence to nintedanib.
Figure 1. Nintedanib adherence trajectories

001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 14of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
8. RESEARCH QUESTION AND OBJECTIVES
This study has two objectives:
1) To assess the association between nintedanib adherence trajectory group (as measured 
from a GBTM) and health care resource use, with a focus on inpatient hospi[INVESTIGATOR_059], among patients with IPF.
2) To assess the association between a patient‚Äôs nintedanib adherence trajectory group
(as measured from a GBTM) and their medical costs among patients with IPF.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 15of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77167] of community-dwelling Medicare beneficiaries with IPF who initiated treatment with nintedanib between 10/01/2014 to 12/31/2018.  To allow for a one-year baseline period and two-year follow-up period for all beneficiaries who initiated nintedanib between 10/01/2014 and 12/31/2018, the span of data 
will be from 10/01/2013 to 12/31/2020.
Figure 2. Study design schematic
9.2 SETTING
9.2.1 Study sites
The study will use 100% Medicare claims and enrollment data from the U.S. Medicare 
program on community-dwelling beneficiaries continuously enrolled in traditional, or fee-for-service, Medicare insurance coverage for inpatient hospi[INVESTIGATOR_307], skilled nursing and outpatient facility services (Part A), physician and other professional services (Part B), and outpatient prescription drugs (Part D). 
The enrollment file contains monthly information on individuals‚Äô enrollment in each part of 
Medicare, demographic information, residential location (at the 5-digit ZIP Code level), and date of death.  
Claims data are available for all medical services covered by [CONTACT_70799].  The Inpatient, Outpatient, and SNF files include institutional claims from hospi[INVESTIGATOR_70777]-stay ‚Äúskilled‚Äù admissions, respectively.  The Carrier file includes fee-for-service claims submitted by [CONTACT_70800], including physicians, physician assistants, clinical social workers, nurse practitioners.  (Claims for some organizational providers, such as free-standing facilities are also found in the Carrier file.  Examples include independent clinical laboratories, ambulance providers, free-standing ambulatory surgical centers, and free-standing radiology centers.)  Separate files include claims for durable medical equipment, home health visits and hospi[INVESTIGATOR_3677].  

001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 16of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Pharmacy Part D claims include complete prescription drug information, and all standardized 
prescription-level fields collected on a typi[INVESTIGATOR_70778] (e.g., date of fill or refill, drug name [CONTACT_70820], strength, quantity, and days‚Äô supply).
9.2.2 Study population
Inclusion criteria:
!Newly initiated nintedanib during 10/01/2014 to 12/31/2018 
!Were at least [ADDRESS_77168] nintedanib prescription 
claim (index date)
!Qualified for Medicare based on age
!Had at least 12 months of continuous enrollment in Medicare Parts A, B and D 
before (baseline period) and 12 months after the index date (follow-up period)
!Had at least one inpatient or two outpatient claims (>14 days apart) with a 
diagnosis code for IPF (ICD-10-CM: J84.112; ICD-9-CM: 516.31) during the 
baseline period
Exclusion criteria:
!Had any history of pi[INVESTIGATOR_70779] 
!Had any history of lung transplant during the baseline, index date or follow-up 
periods 
!Had any claims for skilled nursing facility, long-term care facility or hospi[INVESTIGATOR_70780], index date or follow-up period
!Had evidence ( ‚â•2 ICD-9-CM or ICD-10-CM diagnosis codes on different dates) 
during the baseline period of any of the following conditions: lung cancer, autoimmune, or connective tissue diseases (i.e., rheumatoid arthritis (RA), sarcoidosis, systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren‚Äôs, and mixed connective tissue disease (CTD)) during the baseline period (Appendix-1)
!Had dual eligibility of Medicare and Medicaid.
!Had history of using pi[INVESTIGATOR_70781]-
up
9.2.[ADDRESS_77169]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 17of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77170] likely to belong, given their 12-month pattern of nintdanib claims as estimated from the GBTM.  The groups (and their prevalence in the sample) are highly adherent (43.1%), medium adherent (11.9%), gradual decliners (10.4%), intermediate decliners (13.2%), and rapid decliners (21.5%).
9.3.2 Outcomes
The primary outcome will be total all-cause medical costs, which will be calculated as the 
sum of total amounts paid (by [CONTACT_70801]) for all medical services.  Types of medical services covered by [CONTACT_70802], outpatient f acility, skilled nursing 
facility, home health care, hospi[INVESTIGATOR_6125], durable medical equipment, and clinician office visits (and other services covered under the Part B benefit).  This outcome will exclude spending on outpatient pharmacy (as covered under the Part D benefit).  
The secondary outcomes will be:
1. Total IPF-related medical costs, which will be calculated as the sum of total amounts 
paid (by [CONTACT_70801]) for all medical services for an IPF-related reason (at least one IPF diagnosis code).
2. All-cause inpatient hospi[INVESTIGATOR_059] 3. IPF-related inpatient hospi[INVESTIGATOR_059].
9.3.[ADDRESS_77171] 
whole number will be calculated based on the 
difference between the beneficiary‚Äôs birth date and 
index date. 
Age groupAge group will be a categorical variable for age 
defined as one of 65‚Äì74, 75‚Äì84, 85+.
FemaleFemale will be a binary indicator for whether the 
beneficiary was female as indicated on the enrollment record covering the index date.
RaceRace will be a categorical variable for the 
beneficiary‚Äôs self-reported race/ethnicity taking the 
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 18of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Variable Description
categories Non-Hispanic White, Black or African-
American, Other, Asian/Pacific Islander, Hispanic, American Indian/Alaska Native, and unknown race from the enrollment record covering the index date.
Census regionCensus region will be a categorical variable defined 
by [CONTACT_70803]‚Äôs state of residence into Census regions (Northeast, South, Midwest, West) from the enrollment record covering the index date.
Index yearIndex year will be a categorical variable defined as 
the year of the index date and will take the values, 2014, 2015, 2016, 2017 or 2018.
Social deprivation indexSocial deprivation index will be a continuous 
variable ranging between 0 and 100 representing the Social Deprivation Index for the beneficiary‚Äôs residential ZIP Code as calculated by [CONTACT_70804].  Social Deprivation Index ‚Äúis a composite measure of seven demographic characteristics collected in the American Community Survey (ACS): percent living in poverty, percent with less than 12 years of education, percent single parent household, percent living in rented housing unit, percent living in overcrowded housing unit, percent of households without a car, and percent non-employed adults under 65 years of age.‚Äù  This version was calculated in 2015 using data from 2015 and updates the original version created by [CONTACT_70805]. ( 2013 ).  
Higher values for the Social Deprivation Index indicate more social deprivation.
Clinical characteristics
Combined comorbidity indexThe combined comorbidity index will be a 
continuous comorbidity score ranging from 0 to 26 as measured from comorbidity diagnosis codes in any position on inpatient, outpatient and Carrier claims that occurred during the baseline period.  The combined comorbidity score is based on research by [CONTACT_70806]. ( 2011 ) and Sun et al. ( 2017 ) to identify 
the conditions in the union of the two most-popular comorbidity indexes used in administrative claims data, the Charlson index and the Elixhauser index.  For a sample of Medicare beneficiaries, Gagne et al. (2011) found that a subset of [ADDRESS_77172]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 19of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Variable Description
on their own.  Moreover, unlike the Charlson and 
Elixhauser indexes, Gagne et al.‚Äôs ( 2011 ) combined 
index is not conditioned on inpatient hospi[INVESTIGATOR_063].  The 20 conditions in Gagne et al.‚Äôs (2011) combined comorbidity index (with their weights in parentheses) include: - Metastatic cancer (5), - Congestive heart failure (2), - Dementia (2), - Renal failure (2), - Weight loss (2), - Hemiplegia (1), - Alcohol abuse (1), - Any tumor (1), - Cardiac arrhythmias (1), - Chronic pulmonary disease (1), - Coagulopathy (1), - Complicated diabetes (1), - Deficiency anemia (1), - Fluid and electrolyte disorders (1), - Liver disease (1), - Peripheral vascular disease (1), - Psychosis (1), - Pulmonary circulation disorders (1), - HIV/AIDS ( ‚àí1), and 
- Hypertension ( ‚àí1).
Pulmonary hypertensionA binary indicator for whether the beneficiary had a 
diagnosis code for pulmonary hypertension on at least one inpatient, outpatient or Carrier claim that occurred during the baseline period.
Gastroesophageal refluxA binary indicator for whether the beneficiary had a 
diagnosis code for gastroesophageal reflux disease on at least one inpatient, outpatient or Carrier claim that occurred during the baseline period.
AsthmaA binary indicator for whether the beneficiary had a 
diagnosis code for asthma on at least one inpatient, outpatient or Carrier claim that occurred during the baseline period.
Sleep apneaA binary indicator for whether the beneficiary had a 
diagnosis code for obstructive sleep apnea on at least one inpatient, outpatient or Carrier claim that occurred during the baseline period.
Lung biopsyA binary indicator for whether the beneficiary had a 
diagnosis or procedure code for a lung biopsy on at 
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 20of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77173]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 21of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77174] one inpatient hospi[INVESTIGATOR_70782].
Inpatient stay countA count of the number of inpatient hospi[INVESTIGATOR_70783] a beneficiary had during the baseline period.
Inpatient length of stayA count of the number of days (length of stay) a 
beneficiary was hospi[INVESTIGATOR_70784].  Length of stay for each inpatient hospi[INVESTIGATOR_70785]‚Äôs from and through dates.
Total inpatient spendingA continuous, non-negative variable representing 
the total amount paid by [CONTACT_70807][INVESTIGATOR_602] (for any cause) as reported in inpatient facility claims during the baseline period. This is calculated as the sum of the Medicare payment amount, the Medicare per diem amount, the non-Medicare payer amount, and the patient OOP amount.
OOP inpatient spendingA continuous, non-negative variable representing 
the total amount paid out-of-pocket by [CONTACT_70808][INVESTIGATOR_602] (for any cause) as reported in inpatient facility claims during the baseline period.
Outpatient facility use and spending
Any outpatient visitA binary indicator for whether a beneficiary had at 
least one claim for services provided by [CONTACT_70809].  
Outpatient visit countA count of the number of unique dates with an 
outpatient facility for any cause claim a beneficiary had during the baseline period.
Total outpatient spendingA continuous, non-negative variable representing 
the total amount paid by [CONTACT_70810].  This is calculated as the sum of the Medicare payment amount, the blood deductible liability amount, the non-Medicare payer amount, and the patient OOP amount.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 22of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77175]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 23of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77176] in pulmonary disease that a beneficiary had during the baseline period.  
Pulmonology prescriberA binary indicator for whether the clinician who 
prescribed the beneficiary‚Äôs index nintedanib medication was a pulmonologist, as documented in the Part D Prescriber Characteristics file for the index nintedanib claim.
9.4 DATA SOURCES
The study will use data from the federal Medicare program on elderly beneficiaries 
consistently enrolled in traditional, or fee-for-service, Medicare insurance coverage for hospi[INVESTIGATOR_307] (Part A), physician (Part B) and pharmacy (Part D) claims.  As of October 2021, there were over [ADDRESS_77177], Medicare data capture the 
preponderance of IPF cases.  In a study reported by [CONTACT_70811]. ( 2019 ), 76% of patients on 
nintedanib or pi[INVESTIGATOR_70786] ‚â•65 years of age.  Second, Medicare claims are 
comprehensive in their inclusion of covered services, including outpatient prescription drugs (through Medicare Part D).  Third, there is comparatively little turnover among Medicare beneficiaries compared with commercial insurance enrollees, which means that it is possible to follow Medicare beneficiaries for longer periods on average and more patients will qualify for a study requiring a given minimum continuous coverage period.  Fourth, Medicare claims were used in the prior study of nintedanib adherence, so it is natural to continue using them for this study.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 24of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77178] one claim for 
nintedanib between 10/01/2014 and 12/31/2018.  After sample selection criteria were applied, the final analytic sample consisted of 1,798 patients ( Figure 3 ).
Figure 3. Sample selection in the prior study of nintedanib adherence trajectories
9.[ADDRESS_77179]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 25of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
being copi[INVESTIGATOR_70787] ; only aggregated data based on at least [ADDRESS_77180]‚Äôsbirth and death dates.  The unique patient ID used by  [CONTACT_832] a synthetic identifier, and no 
study staff will have access to the linking file to real subject identifiers.
Additionally, study documents, including synopsis, protocol, and final results as well as 
publications, will be archived on the  Team site.
9.7 DATA ANALYSIS
9.7.1 Main analysis
Descriptive statistics of the covariates will be calculated stratified by [CONTACT_70812]‚Äô adherence trajectory group membership, after assigning patients to the group for which they had the highest posterior probability of membership as estimated in the GBTM (from the prior study).  Tests of joint equality across groups will be computed using ANOVA and nonparametric Kruskal-Wallis rank tests for continuous measures and œá
2tests for 
categorical measures.
Mean outcomes will be compared between pairs of nintedanib adherence trajectory 
membership categories (referent group: highly adherent) using a regression modeling framework.  Unadjusted means will be compared first using an ‚Äúempty‚Äù linear regression model specification (with no covariates or weights) that makes standard errors robust to heteroskedasticity of unknown form.  Adjusted means will then be compared using a ‚Äúdoubly robust‚Äù generalized linear model (GLM) specification that also uses heteroskedasticity-robust standard errors.  More detail about the double-robustness is provided below.
The functional form of the GLM will be selected for each outcome based on its observed 
distribution in the data.  The binary outcome of ‚Äúany hospi[INVESTIGATOR_059]‚Äù will likely be modeled with logistic regression.  The non-negative ‚Äútotal LOS‚Äù outcome may be modeled with a quasi-maximum likelihood Poisson model if the proportion of patients with zero days of hospi[INVESTIGATOR_70788] (less than 10%), or a two-part model (e.g., logistic model of any hospi[INVESTIGATOR_70789]. none and a simultaneously estimated Poisson model of total LOS conditional on having positive LOS) if not ( Belotti et al., 2015 ).  Similarly, if the ‚Äútotal 
medical costs‚Äù outcome has a pi[INVESTIGATOR_5829]-up at zero, a two-part model will be estimated; if not, a GLM with a log link and a distribution family decided by [CONTACT_70813] ( Manning, 1998 ).
Potential confounding by [CONTACT_70814], thus leading to 
‚Äúdoubly robust‚Äù estimates.  The first way is to calculate two sets of observation-level weights that balance covariates across exposure categories: inverse probability of treatment weights (IPTWs) and weights derived from a marginal mean weighting through stratification (MMWS) procedure ( Hong, 2012 ; Linden, 2014 ).  To generate the weights, a multinomial 
logit model of nintedanib adherence trajectory group category will be estimated as a function of the covariate roster.  Predicted probabilities (i.e., propensity scores) for each category will be generated from the model results and used to calculate both the IPTW and MMWS 
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 26of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77181] (ATE) (and not the average treatment effect on the treated [ATT]).  
The second way confounding will be addressed is through regression adjustment; that is, 
observed covariates will be added to the GLM specification.  Combining weighting with regression adjustment yields a double robustness property that attenuates bias in the case when either the treatment model (i.e., the multinomial logit model of exposure category) or the outcome model (i.e., the GLM of the health care resource use or spending outcome) is misspecified ( Linden et al., 2016 ).
To facilitate interpretability, the regression model results will be transformed back to the 
scale of the outcome variable.  Average marginal effects and their 95% confidence intervals (CIs) will be calculated using the delta method.  Data preparation will be performed using SAS 9.4 ( ) and data analysis will be conducted using Stata 17 () .
9.[ADDRESS_77182] and access to the data is being provided by . No additional insight into the data collection procedures is available beyond that which has been published by . As a result, we are relying on quality control measures implemented by 
 [CONTACT_70815].
Regarding quality control procedures around the analyses, the following quality assurance 
and quality control measures will be applied to all programming that executes data extraction and transformation by 
!Check program logs for notes, warning messages, and errors
!Check derived data values against source data for a patient sample to ensure correct 
derivation
!Verify that variables needed to support tables/listings/figures/ are found in the derived 
data set
!Check that data fields are not truncated
!Check data points for values outside expected ranges, where appropriate
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 27of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
!Check that data are rounded correctly and in accordance to the analysis plan
!Check that abbreviations, range categories, and subgroups conform to the analysis 
plan
!Ensure the consistency of sample counts across relevant tables/listings/figures
!Check formats consistent with the analysis plan
!Ensure no typos, misspellings, or false values
!Check that summary statistics are correct; check at least one category in each 
summary table against the data listings
!Check that data are in accordance with the Data Plan
!Check that subgroups conform to the Data Plan
!Ensure there are no duplicate observations
9.9 LIMITATIONS OF THE RESEARCH METHODS
The study has several limitations, including:
!The data source consists of administrative claims data, which do not include 
important determinants of health care resource use and cost outcomes that may be correlated with the adherence exposure, such as IPF disease severity.
!Although the outcomes should be measured accurately, the adherence exposure is 
necessarily based on prescription fill data from claims and may mismeasure actual nintedanib use.
!Sample selection bias may arise from the design decision to exclude patients who do 
not have at least 12 months of follow-up data after nintedanib initiation for primary outcomes (and 24 months for secondary outcomes).
!Generalizability may be limited to IPF patien ts who are continuously covered under 
fee-for-service Medicare, including Parts A, B and D.
9.[ADDRESS_77183] (IRB) review and has been granted a full waiver of HIPAA authorization for use and disclosure of protected health information by [CONTACT_70816].
9.10.[ADDRESS_77184]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 28of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77185]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 29of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
11. MANAGEMENT AND REPORTING OF ADVERSE 
EVENTS/ADVERSE REACTIONS
Given the information available within the Medicare claims database for this study, 
extraction on adverse events data will not be conducted and only data related to the study objectives will be extracted.  Therefore, information about individual adverse events will not be available.  Only data on aggregate-level medication use will be analyzed.
11.[ADDRESS_77186]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 30of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
12. PLANS FOR DISSEMINATING AND COMMUNICATING 
STUDY RESULTS
The results of this study will be considered for dissemination in the form of scientific 
publications (e.g., an abstract/poster for presentation at a national conference, a manuscript for submission to a peer-reviewed journal).
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 31of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77187] DA. Medication adherence trajectories: a 
systematic literature review. Journal of Managed Care & Specialty Pharmacy. 2020 Sep;26(9):1138-52.
Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure 
treatment adherence. Medicine and pharmacy reports. 2019 Apr;92(2):117.
Belotti F, Deb P, Manning WG, Norton EC. twopm: Two-part models. The Stata Journal. 
2015 Apr;15(1):3-20.
Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that 
predict health care access and need within a rational area of primary care service delivery. 
Health services research. 2013 Apr;48(2pt1):539-59.
Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic 
impact of medication non-adherence by [CONTACT_70817]: a systematic review. BMJ open. 2018 Jan 1;8(1):e016982.
Dillon P, Smith SM, Gallagher P, Cousins G. The association between pharmacy refill-
adherence metrics and healthcare utilisation: a prospective cohort study of older hypertensive adults. International Journal of Pharmacy Practice. [ADDRESS_77188];27(5):459-67.
Forbes, C.A., et al., A systematic literature review comparing methods for the measurement 
of patient persistence and adherence. Current medical research and opi[INVESTIGATOR_1649], 2018. 34(9): p. 1613-1625.
Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, Choudhry NK. 
Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepi[INVESTIGATOR_65783]. [ADDRESS_77189];24(10):1105-13.
Franklin JM, Shrank WH, Pakes J, Sanf√©lix-Gimeno G, Matlin OS, Brennan TA, Choudhry 
NK. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Medical care. 2013 Sep 1:789-96.
Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score 
predicted mortality in elderly patients better than existing scores. Journal of clinical epi[INVESTIGATOR_623]. 2011 Jul 1;64(7):749-59.
Hong G. Marginal mean weighting through stratification: a generalized method for evaluating 
multivalued and multiple treatments with nonexperimental data. Psychological methods. 2012 Mar;17(1):44.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 32of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Ipatova AY, Koerner PH, Miller RT, Staskon F, Radi M. Retrospective analysis of 
medication utilization and clinical outcomes in patients with idiopathic pulmonary fibrosis treated with nintedanib or pi[INVESTIGATOR_7735]. Clinical Medicine Insights: Circulatory, Respi[INVESTIGATOR_70790]. 2019 Mar;13:1179548419834922.
Linden A. Combining propensity score ‚Äêbased stratification and weighting to improve causal 
inference in the evaluation of health care interventions. Journal of evaluation in clinical practice. 2014 Dec;20(6):1065-71.
Linden A, Uysal SD, Ryan A, Adams JL. Estimating causal effects for multivalued 
treatments: a comparison of approaches. Statistics in Medicine. 2016 Feb 20;35(4):534-52.
Lo-Ciganic WH, Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, Marcum ZA, 
Gellad WF. Trajectories of diabetes medication adherence and hospi[INVESTIGATOR_70791]: a retrospective cohort study in a large state Medicaid program. Journal of general internal medicine. 2016 Sep;31(9):1052-60.
Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, 
Donohue JM. Association between trajectories of buprenorphine treatment and emergency department and in ‚Äêpatient utilization. Addiction. 2016 May;111(5):892-902.
Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation 
problem. Journal of health economics. 1998 Jun 1;17(3):283-95.
Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annual review 
of clinical psychology. 2010 Apr 27;6:109-38.
Osterberg L, Blaschke T. Adherence to medication. New England journal of medicine. 2005 
Aug 4;353(5):487-97.
Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and 
validation of the combined comorbidity score for ICD-10-CM. Medical care. 2017 Dec 1;55(12):1046-51.
Walsh CA, Cahir C, Tecklenborg S, By[CONTACT_7943] C, Culbertson MA, Bennett KE. The association 
between medication non ‚Äêadherence and adverse health outcomes in ageing populations: A 
systematic review and meta ‚Äêanalysis. British journal of clinical pharmacology. 2019 
Nov;85(11):2464-78.
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 33of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77190]-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 34of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© [ADDRESS_77191](s)NIS not involving BI product(s)
Global NIS Local NIS
NIS Lead X X X
Global TM Epi X X X
Global TMM / TMMA / TM Market 
AccessXX
Global Project Statistician X X
Global TM RA X
Global PVWG Chair X
GPV SC X X X
Global CTIS representative X
Local Medical Director X (if local study) X
Local Head MAcc / HEOR Director X (if local study) X
Global TA Head Epi* X X
Global TA Head Clinical 
Development / Medical Affairs / 
Market Access*XX
Global TA Head PV RM* X
RWE CoE X X
PSTAT / PSTAT-MA
(for NISnd only)XX X
NIS DM X X X
Local Head MA/Clinical 
DevelopmentX (does not apply to 
NISed without chart 
abstraction)
* After review by [CONTACT_70818]: Economic burden associated with nintedanib non-adherence among 
Medicare beneficiaries with IPF
Study Number:
Protocol Version:
001-MCS-90-118_RD-23 (3.0)BOEHRINGER INGELHEIM Group of Companies
NIS Protocol Page 35of 35
BI Study Number 1199-0520 c42255024-02
Proprietary confidential information ¬© 2023 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
I herewith certify that I agree to the content of the study protocol and to all documents 
referenced in the study protocol.
Position: PI _ Name/Date: < > Signature :
[CONTACT_70821]: NIS Lead Name/Date: < > Signature :
[CONTACT_70821]: Name/Date: Signature :
[CONTACT_70821]: Name/Date: Signature :
[CONTACT_70821]: Name/Date: Signature :
[CONTACT_70821]: Name/Date: Signature :
[CONTACT_70821]: Name/Date: Signature :
   
[CONTACT_70822] / SIGNATURE [CONTACT_23364]:  Technical Version Number:
Document Name: 
                                                                                                                  
[CONTACT_1641]: 
                                                                                                                   
Signatures (obtained electronically) 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
  
  
  
  
  
   F 
QLVSURWRFROQLQWHGDQLEY
(FRQRPLFEXUGHQDVVRFLDWHGZLWKQLQWHGDQLEQRQDGKHUHQFHDPRQJ 0HGLFDUH
EHQHILFLDULHVZLWK,3)
$SSURYDO 0D\&(67
$SSURYDO 0D\&(67
$SSURYDO 0D\&(67
$SSURYDO 0D\&(67
$SSURYDO 0D\&(67
$SSURYDO7HDP0HPEHU0HGLFDO
$IIDLUV-XQ&(67
$SSURYDO7HDP0HPEHU'UXJ
6DIHW\-XO&(67
Boehringer Ingelheim Page  2 of 2
Document Number: Technical Version Number :
(Continued) Signatures (obtained electronically) 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
   
   
   
   
   
   
      
   F 